In collaboration with the CORAT consortium of academic and industrial partners, Yumab has found fully human monoclonal antibodies that have neutralizing activity against SARS-CoV-2 in the presence of human cells, according to the company.

Yumab said that its next-generation universal human antibody platform generated hundreds of virus-specific antibody candidates. It also identified additional therapeutic candidates by building antibody libraries from recovered COVID-19 donors. The Helmholtz Center for Infection Research (HZI) then confirmed antibody drug candidates with full neutralization capacity of a patient-derived SARS-CoV-2 strain.

Yumab and its CORAT partners are communicating closely with regulatory authorities regarding the clinical development of antibody drug candidates and clinical studies in humans are expected to begin in the second half of this year, according to the vendor.

Sorrento, Mount Sinai to develop targeted SARS-CoV-2 antibody treatment
Sorrento Therapeutics and Mount Sinai Health System have joined forces to develop an antibody therapy called COVI-Shield to treat COVID-19.

Scientists explore varying immune responses in COVID-19 patients
A new study aims to further classify the immune response of COVID-19 patients with the goal of understanding the pathogenesis of the disease and accelerating...

Pfizer, BioNTech start clinical trials for mRNA COVID-19 vaccine
Clinical trials for a COVID-19 mRNA vaccine developed by Pfizer and BioNTech began on May 5 with New York University Grossman School of Medicine...

Valo to develop pancoronavirus vaccine
Valo Therapeutics announced that it is working on the development of a potential COVID-19 vaccine with applications across future pandemics.

AGC Biologics, AdaptVac partner on COVID-19 vaccine
AGC Biologics, a contract development and manufacturing organization, and AdaptVac have teamed up to develop a COVID-19 vaccine.